Sundaram Maria E, McClure David L, Alonge Oluwakemi D, King Jennifer P, Meece Jennifer K, Nguyen Huong Q
Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
Integrated Research and Development Laboratory, Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
Influenza Other Respir Viruses. 2025 Jul;19(7):e70119. doi: 10.1111/irv.70119.
The burden of human metapneumovirus (hMPV) among community-dwelling high-risk adults is understudied. We calculate the cumulative incidence of outpatient hMPV in high-risk adults, over five consecutive winter respiratory virus seasons (2015-2016 through 2019-2020), and describe clinical characteristics of their illnesses.
We conducted a retrospective analysis of data and respiratory specimens from adults ≥ 18 years old originally participating in a test-negative study of influenza vaccine effectiveness. We included adults with ≥ 1 high-risk condition in 2015-2016 through 2019-2020 seasons. Residual respiratory specimens were retested for hMPV using a multiplex viral panel. We calculated seasonal incidence using Poisson regression and population weighting, with the sum of observed and extrapolated hMPV cases in the study cohort divided by the number of adults with high-risk conditions in the underlying source population.
We tested 3601 respiratory samples; the mean (SD) age of individuals contributing samples was 53 (19) years. We identified 289 individuals (8.0%) with a respiratory sample positive for human metapneumovirus. The estimated seasonal incidence of outpatient hMPV-associated acute respiratory illness was 95.6 (95% CI: 80.5-113.4) cases per 10,000 high-risk adults. These values varied by season, with the highest incidence in 2015-2016 (276.8 cases per 10,000; 95% CI: 210.7-363.5) and lowest in 2016-17 (55.0 cases per 10,000; 95% CI: 31.2-97.0).
We identified substantial seasonal incidence of hMPV cases in community-dwelling high-risk adults in a Wisconsin population cohort.
社区居住的高危成年人中,人偏肺病毒(hMPV)的负担尚未得到充分研究。我们计算了连续五个冬季呼吸道病毒流行季(2015 - 2016年至2019 - 2020年)高危成年人门诊hMPV的累积发病率,并描述了他们疾病的临床特征。
我们对最初参与流感疫苗有效性阴性对照研究的18岁及以上成年人的数据和呼吸道标本进行了回顾性分析。我们纳入了在2015 - 2016年至2019 - 2020年期间患有≥1种高危疾病的成年人。使用多重病毒检测板对剩余的呼吸道标本重新检测hMPV。我们使用泊松回归和人群加权计算季节性发病率,研究队列中观察到的和外推的hMPV病例数之和除以基础源人群中高危疾病成年人的数量。
我们检测了3601份呼吸道样本;提供样本的个体的平均(标准差)年龄为53(19)岁。我们确定了289名个体(8.0%)的呼吸道样本中人偏肺病毒呈阳性。门诊hMPV相关急性呼吸道疾病的估计季节性发病率为每10,000名高危成年人95.6例(95%置信区间:80.5 - 113.4)。这些值因季节而异,2015 - 2016年发病率最高(每10,000名中有276.8例;95%置信区间:210.7 - 363.5),2016 - 17年最低(每10,000名中有55.0例;95%置信区间:31.2 - 97.0)。
我们在威斯康星州人群队列中确定了社区居住的高危成年人中hMPV病例的显著季节性发病率。